Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 7/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CFD | P00746 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19236739 | 0.87 | KDM4E (0.46) | KDM4EHTTALDH1A1LMNAHPGD | |
| SCHEMBL19236913 | 0.77 | KDM4E (0.64) | KDM4EHTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18953236 | 0.72 | TSHR (0.51) | KDM4EHTTALDH1A1LMNAHPGD | |
| SCHEMBL19236884 | 0.70 | CFD (0.40) | LMNATP53ELANECFD | |
| SCHEMBL18562157 | 0.70 | KDM4E (0.65) | KDM4EHTTALDH1A1LMNAHPGD | |
| SCHEMBL12480155 | 0.69 | KDM4E (0.48) | KDM4EHTTALDH1A1LMNAHPGD | |
| SCHEMBL31429288 | 0.69 | TSHR (0.52) | KDM4EHTTALDH1A1LMNAHPGD | |
| SCHEMBL1606609 | 0.69 | TSHR (0.52) | KDM4EHTTALDH1A1LMNAHPGD | |
| SCHEMBL24247716 | 0.69 | ALDH1A1 (0.48) | KDM4EHTTALDH1A1LMNAHPGD | |
| SCHEMBL31429442 | 0.69 | ELANE (0.56) | KDM4EHTTALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | KDM4E 3768/4885HTT 520/4885ALDH1A1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.